LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Trial Details

NCT ID
NCT06216301
Phase
PHASE3
Sponsor
NovoCure GmbH
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • NovoTTF-200T
  • Pembrolizumab
  • Platinum based chemotherapy
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Fullerton, California, United States|33.87029,-117.92534
  • Newport Beach, California, United States|33.61891,-117.92895
  • Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

  • ≥22 years of age in the USA
  • ≥18 years of age outside of the USA.
  • Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer \[AJCC\] criteria) non-squam…
  • Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →